全身糖皮质激素治疗肝硬化合并脓毒性休克患者的临床效果
本研究为回顾性队列研究,纳入2007年1月至2017年5月某三级医院ICU收治的肝硬化合并脓毒性休克患者179例次,其中56例在ICU期间接受糖皮质激素治疗。接受激素者血管升压药总剂量更高(91.2 mg vs 39.1 mg,P=0.04),初始乳酸水平更低(1.8 mmol/L vs 2.6 mmol/L,P=0.007)。多变量分析纳入117例(ICU入住6小时内使用血管升压药者),校正混杂因素后,激素使用与死亡率、ICU入住时间、住院时间、出血事件、谵妄及肾脏替代治疗需求均无显著差异。
要点
- 肝硬化合并脓毒性休克患者中,接受激素者血管升压药总剂量更高(91.2 mg vs 39.1 mg,P=0.04),初始乳酸更低(1.8 mmol/L vs 2.6 mmol/L,P=0.007)。
- 多变量分析纳入117例,激素使用与死亡率、ICU入住时间、住院时间均无显著差异。
- 激素使用与出血事件、谵妄、肾脏替代治疗需求无显著关联。
- 研究为回顾性队列,激素使用与结局的关联需结合患者病情严重程度解读。
适用人群与场景
- 2007年1月至2017年5月某三级医院ICU收治的肝硬化合并脓毒性休克患者,共179例次入院。
- 多变量分析纳入ICU入住6小时内使用血管升压药的患者117例。
研究设计与关键结果
- 研究类型:回顾性队列研究,纳入179例次肝硬化合并脓毒性休克患者,其中56例在ICU期间接受糖皮质激素治疗。
- 接受激素者血管升压药总剂量更高(91.2 mg vs 39.1 mg,P=0.04),初始乳酸水平更低(1.8 mmol/L vs 2.6 mmol/L,P=0.007)。
- 多变量分析纳入117例,校正混杂因素后,激素使用与死亡率、ICU入住时间、住院时间均无显著差异。
- 激素使用与出血事件、谵妄、肾脏替代治疗需求亦无显著关联。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在肝硬化合并脓毒性休克患者中,使用全身糖皮质激素未显示与死亡率、ICU及住院时间改善或不良事件增加相关。
- 接受激素治疗的患者血管升压药需求更高、初始乳酸更低,提示激素使用可能与病情严重程度相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Evidence regarding the utility of systemic steroids in treating patients with cirrhosis and septic shock remains equivocal. This study aimed to evaluate and elucidate the association of steroid use with outcomes and adverse effects in a cohort of patients with cirrhosis and septic shock.
PATIENTS AND METHODS: Retrospective cohort study of patients with cirrhosis and septic shock admitted to a tertiary hospital intensive care unit (ICU) from January 2007 to May 2017, using a validated ICU Datamart. Patients who received vasopressors within 6 h of ICU admission were included in the multivariate analysis. The effect of steroids on outcomes was evaluated using multivariable regression, adjusting for confounding variables.
RESULTS: Out of 179 admissions of patients with cirrhosis and septic shock, 56 received steroids during the ICU admission. Patients who received steroids received a higher total dose of vasopressors (91.2 mg vs. 39.1 mg, P = 0.04) and had a lower initial lactate level (1.8 mmol/L vs. 2.6 mmol/L, P = 0.007). The multivariate analysis included 117 patients and showed no significant differences in mortality, length of ICU admission, or length of hospital stay. Bleeding events, delirium, and renal-replacement therapy requirements were also not associated with the use of steroids.
CONCLUSION: The use of systemic steroids was more prevalent in cirrhotic patients with higher vasopressor requirements. It was not associated with decreased mortality or increased ICU- and hospital-free days, or to adverse effects.
参考来源
- Piccolo Serafim L, Simonetto DA, Anderson AL, et al. Clinical Effect of Systemic Steroids in Patients with Cirrhosis and Septic Shock. Shock. 2021. PMID: 34132218. doi:10.1097/SHK.0000000000001822
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。